BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
NCT: NCT02876042 · COMPLETED
Publicidade
Resumo breve
The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).
Fonte oficial
Ver no ClinicalTrials.gov →Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.